Recent Mercer Communications
If you'd like to be included on future communications, please contact us to join our exclusive distribution list.
HELPING SUPPORT HEALTHCARE'S FOUNDATION DURING THIS TIME OF CHANGE
Mercer has been partnering with states and other stakeholder organizations for over 30 years to support health care programs for the low-income and most vulnerable populations in this country. We face an unprecedented environment of uncertainty and change in the Medicaid and CHIP programs, and yet, there is a need to keep moving forward. This newsletter shares information you need to move your health programs forward.
AFFORDABLE CARE ACT REPEAL AND REPLACE EFFORTS: UNCERTAIN TIMES
After a dramatic journey through the House and the Senate, Congressional efforts to repeal and replace the Affordable Care Act (ACA) are now stalled, with Medicaid a key focus of the Senate deliberations. At the time of the drafting of this article, Senate GOP leadership has announced plans to introduce a repeal and delay bill to repeal ACA but provide Congress...
On August 3rd, the Food and Drug Administration (FDA) approved Mavyret™ (mav-EH'-rit), a new product manufactured by Abbvie for the treatment of hepatitis C virus (HCV). Mavyret™ is approved for the treatment of all six major HCV genotypes for both treatment naïve and treatment experienced patients. Mavyret™ is a combination of two new HCV antivirals, glecaprevir and pibrentasvir. An estimated 95% of patients with chronic hepatitis C in the U.S. could be candidates for treatment with Mavyret™. The list price of Mavyret™ is significantly lower than the list price for other HCV antiviral regimens.
Mavyret™ is a game changer in the Hepatitis C market. Its approval for a short 8-week regimen for treatment naïve patients across all genotypes coupled with a list price that is less than half of the competition will position it well for preferred placement on Medicaid fee-for-service (FFS) and managed care formularies. Abbvie representatives have stated publicly that they are focusing on getting coverage approved through the Medicaid, Medicare, and Veterans Administration markets.
Read more about Indication and Use, Place in Therapy, and Cost